Study #2024-1062
LArotrectiNib to enhance RAI avidity in patients with differentiated thyroid cancer harboring NTRK fusions (LANTERN)
MD Anderson Study Status
Enrolling
Treatment Agent
Larotrectinib monotherapy
Description
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Study phase:
Phase II
Physician name:
Luz Castellanos
Department:
Endocrine Neoplasia and HD
For general questions about clinical trials:
1-888-448-0874
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.